Annovis Bio (ANVS) Competitors $2.86 +0.16 (+5.72%) Closing price 03:58 PM EasternExtended Trading$2.87 +0.01 (+0.21%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANVS vs. ALXO, CYBN, TIL, PBYI, VYGR, TLSA, IMAB, LFVN, ENTA, and IPHAShould you be buying Annovis Bio stock or one of its competitors? The main competitors of Annovis Bio include ALX Oncology (ALXO), Cybin (CYBN), Instil Bio (TIL), Puma Biotechnology (PBYI), Voyager Therapeutics (VYGR), Tiziana Life Sciences (TLSA), I-Mab (IMAB), Lifevantage (LFVN), Enanta Pharmaceuticals (ENTA), and Innate Pharma (IPHA). These companies are all part of the "pharmaceutical products" industry. Annovis Bio vs. Its Competitors ALX Oncology Cybin Instil Bio Puma Biotechnology Voyager Therapeutics Tiziana Life Sciences I-Mab Lifevantage Enanta Pharmaceuticals Innate Pharma Annovis Bio (NYSE:ANVS) and ALX Oncology (NASDAQ:ALXO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk. Do analysts recommend ANVS or ALXO? Annovis Bio currently has a consensus target price of $18.00, indicating a potential upside of 528.27%. ALX Oncology has a consensus target price of $3.30, indicating a potential upside of 603.92%. Given ALX Oncology's higher possible upside, analysts clearly believe ALX Oncology is more favorable than Annovis Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Annovis Bio 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00ALX Oncology 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71 Which has stronger valuation & earnings, ANVS or ALXO? Annovis Bio is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnnovis BioN/AN/A-$24.59M-$2.16-1.33ALX OncologyN/AN/A-$134.85M-$2.47-0.19 Is ANVS or ALXO more profitable? ALX Oncology's return on equity of -104.43% beat Annovis Bio's return on equity.Company Net Margins Return on Equity Return on Assets Annovis BioN/A -300.56% -193.50% ALX Oncology N/A -104.43%-77.74% Which has more volatility & risk, ANVS or ALXO? Annovis Bio has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500. Comparatively, ALX Oncology has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500. Do insiders & institutionals believe in ANVS or ALXO? 15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 98.0% of ALX Oncology shares are owned by institutional investors. 20.8% of Annovis Bio shares are owned by company insiders. Comparatively, 21.0% of ALX Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media favor ANVS or ALXO? In the previous week, ALX Oncology had 4 more articles in the media than Annovis Bio. MarketBeat recorded 4 mentions for ALX Oncology and 0 mentions for Annovis Bio. ALX Oncology's average media sentiment score of 0.29 beat Annovis Bio's score of 0.00 indicating that ALX Oncology is being referred to more favorably in the news media. Company Overall Sentiment Annovis Bio Neutral ALX Oncology Neutral SummaryALX Oncology beats Annovis Bio on 9 of the 14 factors compared between the two stocks. Get Annovis Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANVS vs. The Competition Export to ExcelMetricAnnovis BioMED IndustryMedical SectorNYSE ExchangeMarket Cap$55.84M$2.95B$5.53B$20.66BDividend YieldN/A2.43%5.06%3.71%P/E Ratio-1.3321.1628.5827.83Price / SalesN/A184.61372.6456.10Price / CashN/A41.0524.7217.94Price / Book4.287.748.234.60Net Income-$24.59M-$55.05M$3.19B$989.58M7 Day Performance19.87%12.77%5.46%1.16%1 Month Performance1.78%13.59%9.39%5.49%1 Year Performance-76.44%4.43%30.48%10.60% Annovis Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANVSAnnovis Bio1.5702 of 5 stars$2.87+5.7%$18.00+528.3%-77.6%$55.84MN/A-1.333ALXOALX Oncology3.5885 of 5 stars$0.44-3.5%$3.30+643.2%-93.2%$24.57MN/A-0.1840News CoverageNegative NewsCYBNCybin2.5113 of 5 stars$7.87-0.9%$86.00+992.8%N/A$181.20MN/A-1.8050TILInstil Bio3.4586 of 5 stars$23.64-14.0%$119.00+403.4%+92.5%$180.37MN/A-1.97410High Trading VolumePBYIPuma Biotechnology4.2391 of 5 stars$3.54-1.1%$7.00+97.7%-5.6%$177.68M$230.50M4.60200VYGRVoyager Therapeutics3.978 of 5 stars$3.04-5.0%$13.39+340.5%-60.2%$177.08M$80M-2.08100TLSATiziana Life Sciences1.3539 of 5 stars$1.53+1.3%N/A+83.2%$176.44MN/A0.008IMABI-Mab2.8887 of 5 stars$2.09-2.8%$6.00+187.1%+23.8%$175.57M$3.89M0.00380Analyst UpgradeLFVNLifevantage4.3295 of 5 stars$13.59-0.9%$30.50+124.4%+96.7%$172.71M$200.16M19.70260ENTAEnanta Pharmaceuticals3.9126 of 5 stars$7.65-3.0%$18.00+135.3%-59.0%$168.66M$67.64M-1.69160IPHAInnate Pharma2.6309 of 5 stars$1.79-1.6%$11.00+514.5%-21.7%$167.76M$21.77M0.00220 Related Companies and Tools Related Companies ALX Oncology Competitors Cybin Competitors Instil Bio Competitors Puma Biotechnology Competitors Voyager Therapeutics Competitors Tiziana Life Sciences Competitors I-Mab Competitors Lifevantage Competitors Enanta Pharmaceuticals Competitors Innate Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ANVS) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annovis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annovis Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
